Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on ... in Cardiovascular Medicine, 100) - Image 1

£163.98

Springer Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on ... in Cardiovascular Medicine, 100)

Name: Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on ... in Cardiovascular Medicine, 100)
Brand: Springer
Price: 163.98 GBP
Availability: InStock

Cardiovascular

This is the usual price. Wait for it to drop, or tell us your number.

£164 today · usual range £129–£166 · best ever £129

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 72 days · 72 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 72 days • 5 price levels

Days at Price

Current Price

Price Analysis

Most common price: £166 (44 days, 61.1%)

Price range: £129 - £166

Price levels: 5 different prices over 72 days

Description

The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall strategies regarding post- x thrombolytic care and relationships to sudden cardiac death were also detailed. The panel discussion sections provided a comprehensive view of the current thinking of the various participating groups in this symposium. Sudden cardiac death remains the number one cause of mortality in western industrialized societies.

Product Specifications

Brand: Springer
Format: hardcover
ASIN: 079230294X
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Cardiovascular
Domain: Amazon UK
Release Date: 30 June 1989
Listed Since: 15 February 2007

Barcode

No barcode data available

Springer Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on ... in Cardiovascular Medicine, 100)

This is the usual price. Wait for it to drop, or tell us your number.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on ... in Cardiovascular Medicine, 100)

The Modern Era of Coronary Thrombolysis: 160 (Developments in Cardiovascular Medicine, 160)

Sudden Cardiac Death: A Handbook for Clinical Practice: 6 (European Society of Cardiology)

Ventricular Fibrillation and Sudden Coronary Death: 219 (Developments in Cardiovascular Medicine, 219)

Sudden Cardiac Death: Past, Present and Future (American Heart Association Monograph S.)

Myocardial Ischemia and Arrhythmia: Under the auspices of the Society of Cooperation in Medicine and Science (SCMS), Freiburg, Germany

Early Interventions in Acute Myocardial Infarction: 97 (Developments in Cardiovascular Medicine, 97)

Triggering of Acute Coronary Syndromes: Implications for Prevention: 170 (Developments in Cardiovascular Medicine, 170)

SUDDEN CARDIAC DEATH: Epidemiology, Genetics & Predictive / Prevention Strategies (Cardiology Research and Clinical Developments)

Early Interventions in Acute Myocardial Infarction: 97 (Developments in Cardiovascular Medicine)

Atrial Fibrillation and Percutaneous Coronary Intervention: A Case-based Guide to Oral Anticoagulation, Antiplatelet Therapy and Stenting

Wiley Cardiology at its Core - Medical Textbook for Clinicians

Kompendium der koronaren Herzkrankheit: Ergänzt mit Antworten auf Fragen zu den einzelnen Themen

Antiarrhythmic Drugs (Current Cardiovascular Therapy)

Coronary Care Medicine: A Practical Approach

Pathobiology of Cardiovascular Injury: From the proceedings of the Meeting of the American Section of the International Society for Heart Research ... (Developments in Cardiovascular Medicine, 49)

12 Lead ECG Interpretation in Acute Coronary Syndrome with Case Studies from the Cardiac Catheterization Lab

Autonome Innervation des Herzens Myokardiale Hypoxie

Cardiogenic Shock: 8 (American Heart Association Clinical Series)

The 12-Lead ECG in Acute Coronary Syndromes

Ventricular Fibrillation and Sudden Coronary Death: 219 (Developments in Cardiovascular Medicine, 219)